

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: January 31, 2005, 16:14:26 ; Search time 0.001 Seconds
(without alignments)
537.732 Million cell updates/sec

Title: us-10-063-553-47

Perfect score: 766

Sequence: 1 ggctcgagcgtttcttgagcc.....agtagtttgaaaaa 766

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 1 seqs, 351 residues

Total number of hits satisfying chosen parameters: 2

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : us-09-803-719-950.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	285.2	34.6	351	1	us-09-803-719-950
2	21.6	2.8	351	1	us-09-803-719-950

ALIGNMENTS

RESULT 1
us-09-803-719-950

Query Match	34.6%;	Score 265.2;	DB 1;	Length 351;
Best Local Similarity	91.0%;	Pred. No. 0;		
Matches	303;	Conservative 0;	Mismatches 28;	Indels 2; Gaps 2;
Qy	7	AGCGTTTCTTGAGCGGCGTGACCATGACCTGCTGCGAAGGATGACATCTCTGCAATGGA	66	
Db	18	AACGCTCTGTGCCATCGGTGACCATGACCTGCTGATAGGATGACATCTCTGCTAGTA	77	
Qy	67	TTGAGCTGTGTTCTACTGCTTTAGGAGTAGTTCTCAATGCGATACCT-CTAATTGT	125	
Db	78	CTCAACCTGTGCTGCTTTACTGCTGGTAGGAGTCGTTCTCACTGGGACACCTGCTTAATTGT	137	
Qy	126	CAGCTTAGTT- GAGGAAGACCAATTTCTCAAAACCCCATCTCTTGCTTTGAGTGGT	184	
Db	138	CATATTATTTAGAGGAAGACCAATTTGTCTCAAAAGCCCATCTCTTGCTTTGAGTGGT	197	
Qy	185	TCCAGGAATTTATAGGAGCGTCTGATGGCCATTTCAGCAACAACAAATGTCCTTGACAG	244	
Db	198	TCCACGAATTTATAGGAGCGTCTGATGGCCATTTCAGCAACAACAAATGTCCTTGACAG	257	
Qy	245	CAAGAAAAGAGCGTGTGCAACACAGAACTGGAATGTTTCTTTTCATCATTTTCAAGTG	304	
Db	258	CAAGAAAAGAGCGTGTGCAACACAGAACTGGAATGTTTCTTTTCATCATTTTCAAGTG	317	

Qy 305 TGATCAGATCATTTGGTGCTCTGTATTGCATGC 337
Db 318 TGATCAGATCATTTGGTGCTCTGTATTGCATGC 350

RESULT 2

us-09-803-719-950/c

Query Match 2.8%; Score 21.6; DB 1; Length 351;
Best Local Similarity 51.0%; Pred. No. 0;
Matches 51; Conservative 0; Mismatches 49; Indels 0; Gaps 0;
Qy 225 AACAAATGTCTTTGACAGCAAGAAAAGAGCGTGTGCAACACAGAACTGGAATGTT 284
Db 337 AGCACCATGACTGTGATCAGACTGAAAAGTGAAGAAGAAATTCAGTTCTGTTGTT 278
Qy 285 TCTTTCAATTTTTTCAGTGTGATCAGATCATTTGGTGCT 324
Db 277 GCAGCAGCTCTTTTCTTCTGCTGTCAGGACATTTGTTT 238

Search completed: January 31, 2005, 16:14:26
Job time : 0.001 secs

This Page Blank (uspto)

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: January 31, 2005, 16:18:13 ; Search time 0.001 Seconds
(without alignments)
438.152 Million cell updates/sec

Title: us-10-063-553-47
Perfect score: 766
Sequence: 1 ggctcgagctttctgagcc.....agtagttgaaaaa 766

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 1 seqs, 286 residues

Total number of hits satisfying chosen parameters: 2

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : aaf98695.geneseqn200lbs.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result	No.	Score	Query Match	Length	ID	Description
c	1	231.4	30.2	286	1 AAF98695	Human ovarian canc
	2	16.6	2.2	286	1 AAF98695	Human ovarian canc

ALIGNMENTS

RESULT 1
AAF98695
ID AAF98695 standard; DNA; 286 BP.
XX
AC AAF98695;
XX
DT 02-JUL-2001 (first entry)
XX
DE Human ovarian cancer cell expressed sequence 10793.
XX
KW Human; ovarian cancer; identification; detection; characterisation;
KW tumour; kinase; marker; cytostatic; antisense gene therapy; ds.
XX
OS Homo sapiens.
XX
PN WO200118542-A2.
XX
PD 15-MAR-2001.
XX
PF 01-SEP-2000; 2000WO-US024199.
XX
PR 03-SEP-1999; 99US-0152547P.
PR 16-MAR-2000; 2000US-0190347P.
PR 21-MAR-2000; 2000US-0191321P.
PR 31-MAY-2000; 2000US-0208382P.
PR 20-JUL-2000; 2000US-00220467.

XX PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX PI Lee J, Thompshe P, Lillie J;
XX DR MPI; 2001-211428/21.
XX PT Detection, assessment, prevention and therapy of ovarian cancer,
XX PT comprises detecting changes in the expression of a variety of markers.
XX PS Claim 1; Page 998-999; 1198pp; English.
XX CC The present invention describes a method for assessing whether a patient
CC is afflicted with ovarian cancer by comparing: (1) the expression of a
CC marker (1) (see AAF98594 to AAF98730), in a patient sample; and (2) the
CC normal level of expression of (1) in a control non-ovarian cancer sample,
CC where a significant difference between the level of expression in (a) and
CC (b) is an indication that the patient is afflicted with ovarian cancer.
CC (1) have cytostatic activities and can be used in antisense gene therapy.
CC The method, compositions and kits from the present invention can be used
CC for: (1) assessing and treating ovarian cancer; (2) making isolated
CC hybridoma, which produces an antibody useful for ovarian cancer
CC assessment; and (3) inhibiting ovarian cancer in a patient. AAF98573 to
CC AAF98593 represent human kinase marker primers and probes which are used
CC in the exemplification of the present invention
XX SQ Sequence 286 BP; 65 A; 69 C; 76 G; 76 T; 0 U; 0 Other;
Query Match 30.2%; Score 231.4; DB 1; Length 286;
Best Local Similarity 99.6%; Pred. No. 0;
Matches 232; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 7 AGCGTTTCTGAGCCAGGGGTGACCATGACCTGCTGCGAAGGATGACATCCTCGCAATGGA 66
Db 48 AAGTTTCTGAGCCAGGGGTGACCATGACCTGCTGCGAAGGATGACATCCTCGCAATGGA 107
Qy 67 TTCAGCCTGCTGTTCTACTGCTGTAGGAGTAGTTCTCAATGCGATACCTCTAATTGTC 126
Db 108 TTCAGCCTGCTGTTCTACTGCTGTAGGAGTAGTTCTCAATGCGATACCTCTAATTGTC 167
Qy 127 AGCTTAGTTCAGGAGAGACCAATTTCTCAAAACCCCATCTCTTCTTGTAGTGTGTTTC 186
Db 168 AGCTTAGTTCAGGAGAGACCAATTTCTCAAAACCCCATCTCTTCTTGTAGTGTGTTTC 227
Qy 187 CCAGGAATTATAGGAGCAGGTCTGATGGCCATTCCAGCAACCAATGTCCTT 239
Db 228 CCAGGAATTATAGGAGCAGGTCTGATGGCCATTCCAGCAACCAATGTCCTT 280
RESULT 2
AAF98695/c
ID AAF98695 standard; DNA; 286 BP.
XX
AC AAF98695;
XX
DT 02-JUL-2001 (first entry)
XX
DE Human ovarian cancer cell expressed sequence 10793.
XX
KW Human; ovarian cancer; identification; detection; characterisation;
KW tumour; kinase; marker; cytostatic; antisense gene therapy; ds.
XX
OS Homo sapiens.
XX
PN WO200118542-A2.
XX
PD 15-MAR-2001.
XX
PF 01-SEP-2000; 2000WO-US024199.
XX
PR 03-SEP-1999; 99US-0152547P.
PR 16-MAR-2000; 2000US-0190347P.
PR 21-MAR-2000; 2000US-0191321P.
PR 31-MAY-2000; 2000US-0208382P.
PR 20-JUL-2000; 2000US-00220467.

```

PR 31-MAY-2000; 2000US-0208382P.
PR 20-JUL-2000; 2000US-00220467.
XX
XX (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX
XX Lee J, Thompsho P, Lillie J;
XX
XX WPI; 2001-211428/21.
XX
XX Detection, assessment, prevention and therapy of ovarian cancer,
XX comprises detecting changes in the expression of a variety of markers.
XX
XX Claim 1; Page 998-999; 1198pp; English.
XX
XX The present invention describes a method for assessing whether a patient
XX is afflicted with ovarian cancer by comparing: (1) the expression of a
XX marker (1) (see AAF98594 to AAF98730), in a patient sample; and (2) the
XX normal level of expression of (1) in a control non-ovarian cancer sample,
XX where a significant difference between the level of expression in (a) and
XX (b) is an indication that the patient is afflicted with ovarian cancer.
XX (1) have cytostatic activities and can be used in antisense gene therapy.
XX The method, compositions and kits from the present invention can be used
XX for: (1) assessing and treating ovarian cancer; (2) making isolated
XX hybridoma, which produces an antibody useful for ovarian cancer
XX assessment; and (3) inhibiting ovarian cancer in a patient. AAF98573 to
XX AAF98593 represent human kinase marker primers and probes which are used
XX in the exemplification of the present invention
XX
SQ Sequence 286 BP; 65 A; 69 C; 76 G; 76 T; 0 U; 0 Other;

Query Match      2.2%; Score 16.6; DB 1; Length 286;
Best Local Similarity 52.1%; Pred.No. 0;
Matches 37; Conservative 0; Mismatches 34; Indels 0; Gaps 0;

Qy 359 TAAAGGTCCTCTCATGTGTAATTCCTCAAGCAACAGTAATGCCAATTCGTAATTTTCAT 418
Db 162 TTAGAGGTATCGCATTGAGAACTACTCTTAACAGCAGTAGAACCCAGCGCTGAATCCAT 103

Qy 419 TGAATAACATC 429
Db 102 TGCAGGATGTC 92

```

Search completed: January 31, 2005, 16:18:13
Job time : 0.001 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: January 31, 2005, 16:16:07 ; Search time 0.001 Seconds
(without alignments)
1124.488 Million cell updates/sec

Title: us-10-063-553-47
Perfect score: 766
Sequence: 1 ggctcgagcgtttcttgagcc.....agtagtttgaaaaa 766

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 1 seqs, 734 residues

Total number of hits satisfying chosen parameters: 2

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : aak88578.geneseqn2001as.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result	No.	Score	Query Match	Length	DB ID	Description
c	1	430.1	56.1	734	1 AAK88578	Human digestive sy
	2	19	2.5	734	1 AAK88578	Human digestive sy

ALIGNMENTS

RESULT 1
AAK88578
ID AAK88578 standard; cDNA; 734 BP.
XX
AC AAK88578;
XX
DT 05-NOV-2001 (first entry)
XX
DE Human digestive system antigen coding sequence SEQ ID NO: 894.
XX
KW Human; digestive system antigen; gene therapy; cancer; appendicitis;
KW ulcerative colitis; infection; Hirschsprung's disease; chronic colitis;
KW digestive system disorder; Meckel's diverticulum; ss.
XX
OS Homo sapiens.
XX
PN WO200155314-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US001324.
XX
PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.

16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226868P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 06-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 02-OCT-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.

PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209457P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 14-AUG-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 18-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226868P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234957P.
PR 26-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.

PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254037P.
PR 05-JAN-2001; 2001US-02559678P.

(HUMA-) HUMAN GENOME SCI INC.

Rosen CA, Barash SC, Ruben SM;

WPI; 2001-502630/55.

P-PSDB; AAM92805.

Polynucleotides encoding digestive system antigens, useful for diagnosing, treating, preventing and/or prognosing disorders of the digestive system, particularly cancer and cancer metastases.

Claim 1; SEQ ID NO 894; 986pp; English.

XX

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: January 31, 2005, 16:17:18 ; Search time 0.001 Seconds
(without alignments)
537.732 Million cell updates/sec

Title: us-10-063-553-47

Perfect score: 766

Sequence: 1 ggctcgagctttcttgagcc.....agtagtttgaataaaaaa 766

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 1 seqs, 351 residues

Total number of hits satisfying chosen parameters: 2

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : aas37892.geneseqn2001as.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result	No.	Score	Query Match	Length	ID	Description
1	265.2	34.6	351	1	AAS37892	Novel human diagno
2	21.6	2.8	351	1	AAS37892	Novel human diagno

ALIGNMENTS

RESULT 1

AAS37892
ID AAS37892 standard; cDNA; 351 BP.

XX AAS37892;

DT 17-DEC-2001 (first entry)

DE Novel human diagnostic and therapeutic gene #950.

XX Human; cancer; breast; lung; colon; prostate; cytostatic; diagnostic; ss.

XX Homo sapiens.

XX WO200166753-A2.

XX 13-SEP-2001.

XX 09-MAR-2001; 2001WO-US007787.

XX 09-MAR-2000; 2000US-0188609P.

XX (CHIR) CHIRON CORP.

XX (HYSE-) HYSEQ INC.

XX Williams LT, Escobedo J, Innis MA, Garcia PD, Sudduth-Klinger J;

PI Reinhard C, Randazzo F, Kennedy GC, Pot D, Kassam A, Lamson G;
PI Drmanac R, Crkvenjakov R, Dickson M, Drmanac S, Labat I;
XX Leshkowitz D, Kita D, Garcia V, Jones WL, Stache-Crain B;
XX WPI; 2001-530177/58.

XX New polynucleotides and polypeptides, useful for diagnosis and treatment
of breast, lung and colon cancer.

XX Claim 1; Page 836; 1193pp; English.

XX The invention relates to new polynucleotides and polypeptides, useful for
diagnosis and treatment of breast, lung and colon cancer. The sequences
can be used in detecting differentially expressed genes correlated with a
cancerous state of a mammalian cell, comprising detecting at least one
differentially expressed gene product in a test sample derived from a
cell suspected of being cancerous. They can also be used to inhibit
tumour growth by modulating expression of a gene product. AAS36943-
AAS39338 represent novel human diagnostic and therapeutic coding
sequences of the invention

XX Sequence 351 BP; 87 A; 86 C; 80 G; 97 T; 0 U; 1 Other;

Query Match 34.6%; Score 265.2; DB 1; Length 351;

Best Local Similarity 91.0%; Pred. No. 0;

Matches 303; Conservative 0; Mismatches 28; Indels 2; Gaps 2;

Qy 7 AGCGTTTCTGAGCCAGGGGTGACCATGACCTGCTGCCAAGGATGACATCTCTGCAATGGA 66

Db 18 AACGCTCTGTGCCATCGTGACCATGACCTGCTGTAAGGATGACATCTCTGCTAGTA 77

Qy 67 TTCAGCTGCTGGTTCTACTGCTTACTAGGAGTAGTCTCAATGCGATACCT-CTAATTGT 125

Db 78 CTCAACTGCTGCTTCTACTGCTGCTAGGAGTCTCTACTGCGACACCTGCTAATTGT 137

Qy 126 CAGCTTAGTT-GAGGAAGACCAATTTTCTCAAAACCCCATCTCTTGCTTTGAGTGGTGT 184

Db 138 CATATTATTAGAGGAAGACCAATTTGCTCAAAAGCCCATCTCTTGCTTTCAGTGGTGT 197

Qy 185 TCCAGCAATATAGGAGCAGGTCTGATGCCATTCCAGCAACACATGCTCTTGACAG 244

Db 198 TCCACAGCAATATAGGAGCAGGTCTGATGCCATTCCAGCAACACATGCTCTTGACAG 257

Qy 245 CAAGAAAAAGAGCGTCTGCAACACAGAACTGGAATGTTTCTTTCATCATTTTTCAGTG 304

Db 258 CAAGAAAAAGAGCGTCTGCAACACAGAACTGGAATGTTTCTTTCATCATTTTTCAGTG 317

Qy 305 TGATCACAGTCATTGGTCTCTGCTGATTGCGATGC 337

Db 318 TGATCACAGTCATTGGTCTCTGCTGATTGCGATGC 350

RESULT 2

AAS37892/c

ID AAS37892 standard; cDNA; 351 BP.

XX AAS37892;

DT 17-DEC-2001 (first entry)

DE Novel human diagnostic and therapeutic gene #950.

XX Human; cancer; breast; lung; colon; prostate; cytostatic; diagnostic; ss.

XX Homo sapiens.

XX WO200166753-A2.

XX 13-SEP-2001.

XX 09-MAR-2001; 2001WO-US007787.

XX 09-MAR-2000; 2000US-0188609P.

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: January 31, 2005, 16:19:09 ; Search time 0.001 Seconds
(without alignments)
579.096 Million cell updates/sec

Title: us-10-063-553-47

Perfect score: 766

Sequence: 1 ggctcgagcgtttcttgagcc.....agtagtttgaataaaaaa 766

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 1 seqs, 378 residues

Total number of hits satisfying chosen parameters: 2

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : aas38101.geneseqn2001as:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	148.6	19.4	378	1 AAS38101	Novel human diagno
2	18	2.3	378	1 AAS38101	Novel human diagno

ALIGNMENTS

RESULT 1
AAS38101
ID AAS38101 standard; cDNA; 378 BP.

XX AAS38101;

DT 17-DEC-2001 (first entry)

DE Novel human diagnostic and therapeutic gene #1159.

XX Human; cancer; breast; lung; colon; prostate; cytostatic; diagnostic; ss.

OS Homo sapiens.

PN WO200166753-A2.

XX 13-SEP-2001.

XX 09-MAR-2001; 2001WO-US007787.

PR 09-MAR-2000; 2000US-0188609P.

XX (CHIR) CHIRON CORP.

PA (HYSE-) HYSEQ INC.

XX Williams LT, Escobedo J, Innis MA, Garcia PD, Sudduth-Klinger J;

PI Reinhard C, Randazzo F, Kennedy GC, Pot D, Kassam A, Lamson G;
PI Drmanac R, Crkvenjakov R, Dickson M, Drmanac S, Labat I;
XX Leshkowitz D, Kita D, Garcia V, Jones WL, Stache-Crain B;
DR WPI; 2001-530177/58.

XX New polynucleotides and polypeptides, useful for diagnosis and treatment
of breast, lung and colon cancer.

PS Claim 1; Page 887; 1193pp; English.

XX The invention relates to new polynucleotides and polypeptides, useful for
diagnosis and treatment of breast, lung and colon cancer. The sequences
can be used in detecting differentially expressed genes correlated with a
cancerous state of a mammalian cell, comprising detecting at least one
differentially expressed gene product in a test sample derived from a
cell suspected of being cancerous. They can also be used to inhibit
tumour growth by modulating expression of a gene product. AAS38101-
AAS39338 represent novel human diagnostic and therapeutic coding
sequences of the invention

SQ Sequence 378 BP; 112 A; 75 C; 73 G; 118 T; 0 U; 0 Other;

Query Match 19.4%; Score 148.6; DB 1; Length 378;

Best Local Similarity 89.4%; Pred. No. 0;

Matches 160; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 158 ACCCATCTCTGCTTTGAGTGGTTCACGACGAGAAATATAGGAGCAGGCTGATGGCA 217

DB 199 ACCCATCTCTGCTTTGAGTGGGCGTCCCAAGAAATATAGGAGGCGTATGGCA 258

QY 218 TTCAGCAACAAATGCTCTTGACGACGAGAAAGAGGCTGCAACACAGAACTG 277

DB 259 TTTGAGGACACACATGCTCTTGACACACAAAAAAGATCGTGTTCACACAGAAATG 318

QY 278 GAATGTTCTTTCATCATTTTTCAGTGTGATFCACAGTCATTTGCTCTGTATTGCATG 336

DB 319 CAATGTTCTTTCATCATTTTTCAGTGTGATFCACAGTCATTTGCTCTGTATTGCATG 377

RESULT 2

AAS38101/c

ID AAS38101 standard; cDNA; 378 BP.

XX AAS38101;

DT 17-DEC-2001 (first entry)

DE Novel human diagnostic and therapeutic gene #1159.

XX Human; cancer; breast; lung; colon; prostate; cytostatic; diagnostic; ss.

OS Homo sapiens.

PN WO200166753-A2.

XX 13-SEP-2001.

XX 09-MAR-2001; 2001WO-US007787.

PR 09-MAR-2000; 2000US-0188609P.

XX (CHIR) CHIRON CORP.

PA (HYSE-) HYSEQ INC.

XX Williams LT, Escobedo J, Innis MA, Garcia PD, Sudduth-Klinger J;

PI Reinhard C, Randazzo F, Kennedy GC, Pot D, Kassam A, Lamson G;

PI Drmanac R, Crkvenjakov R, Dickson M, Drmanac S, Labat I;

PI Leshkowitz D, Kita D, Garcia V, Jones WL, Stache-Crain B;

XX WPI; 2001-530177/58.

XX New polynucleotides and polypeptides, useful for diagnosis and treatment

```

PT of breast, lung and colon cancer.
XX
XX Claim 1; Page 887; 1193pp; English.
XX
XX The invention relates to new polynucleotides and polypeptides, useful for
XX diagnosis and treatment of breast, lung and colon cancer. The sequences
XX can be used in detecting differentially expressed genes correlated with a
XX cancerous state of a mammalian cell, comprising detecting at least one
XX differentially expressed gene product in a test sample derived from a
XX cell suspected of being cancerous. They can also be used to inhibit
XX tumour growth by modulating expression of a gene product. AAS36943-
XX AAS39338 represent novel human diagnostic and therapeutic coding
XX sequences of the invention
XX
XX Sequence 378 BP; 112 A; 75 C; 73 G; 118 T; 0 U; 0 Other;
XX
XX Query Match 2.3%; Score 18; DB 1; Length 378;
XX Best Local Similarity 49.0%; Pred. No. 0;
XX Matches 48; Conservative 0; Mismatches 50; Indels 0; Gaps 0;
XX
QY 225 AACAAACAATGTCCTTGACAGCAAGAAAAAGCGGTGCTGCAACACACAGAACTGGGAATGTT 284
XX
Db 365 AGCGCCAACTAGCTGTGATCACACTGAAAGTGATAAAGAAACATGTGATTCTCTGTTGTT 306
XX
QY 285 TCTTTCATCATTTTTCAGTGTGATCA CAGTCATTGTG 322
XX
Db 305 GAAGCAGCATCTTTTTTTTTTTGTTGTCAAGGACATTGTTG 268
XX

```

Search completed: January 31, 2005, 16:19:09
Job time : 0.001 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: January 31, 2005, 16:21:35 ; Search time 0.001 Seconds
(without alignments)
91.920 Million cell updates/sec

Title: us-10-063-553-47
Perfect score: 766
Sequence: 1 ggctcgagcgttctgagcc.....agtagttgaaaaa 766

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 1 seqs, 60 residues

Total number of hits satisfying chosen parameters: 2

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : abn47584.geneseqm2002as.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	60	7.8	60	1 ABN47584	Human spliced tran
2	9.8	1.3	60	1 ABN47584	Human spliced tran

ALIGNMENTS

RESULT 1
ABN47584
ID ABN47584 standard; DNA; 60 BP.
XX
XX
AC ABN47584;
XX
XX 15-JUL-2002 (first entry)
XX
XX Human spliced transcript detection oligonucleotide SEQ ID NO:20332.
DE
XX Human; mouse; rat; splice transcript; detection; RNA transcript;
KW splice variant; transcriptome; oligonucleotide library; ss.
XX
XX Homo sapiens.
XX
XX WO200210449-A2.
XX
XX 07-FEB-2002.
XX
XX 20-JUL-2001; 2001WO-IB001903.
XX
XX 28-JUL-2000; 2000US-0221607P.
PR
XX 02-MAY-2001; 2001US-0287724P.
XX
XX (COMP-) COMPUGEN INC.

PI Shoshan A, Wasserman A, Mintz E, Mintz L, Faigler S;
XX WPI; 2002-257383/30.
XX
XX New oligonucleotide libraries comprising oligonucleotides which
PT selectively hybridize to mRNAs transcribed from a transcription unit of a
PT genome, useful for detecting tissue-, pathology-, and developmental-
PT specific genes.
XX
XX Example 1; SEQ ID NO 20332; 47pp; English.
XX
XX The present invention describes oligonucleotide libraries for detecting
CC messenger RNAs that populate a (sub-)transcriptome, where the (sub-
CC)transcriptome comprises messenger RNAs transcribed from multiple
CC transcription units that populate a genome. The library comprises several
CC oligonucleotides, each capable of hybridising selectively to a set of
CC messenger RNAs transcribed from a given transcription unit of the genome,
CC which encodes one or more messenger RNA splice variants. The
CC oligonucleotide libraries are useful for detecting mRNAs from a
CC biological sample, in expression profiling studies, in qualitatively or
CC quantitatively characterising the corresponding transcriptome, and in
CC detecting RNA transcripts and splice variants of human or animal
CC transcriptomes. The libraries may also be used as specialised mini
CC libraries to detect transcripts of a sub-transcriptome under a particular
CC biological or pathological state, and so allowing the detection of tissue
CC - and pathology-specific genes such as those genes only expressed in
CC specific tissue under a specific pathological condition; to detect
CC developmental specific genes; and to detect RNA transcripts and splice
CC variants of a transcriptome of a patient suffering from a particular
CC disorder. ABN27253 to ABN59589 represent oligonucleotide sequences from
CC rats, humans and mice, which are used in the exemplification of the
CC present invention. N.B. The sequence data for this patent did not form
CC part of the printed specification, but was obtained in electronic format
CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 60 BP; 16 A; 14 C; 16 G; 14 T; 0 U; 0 Other;

Query Match 7.8%; Score 60; DB 1; Length 60;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 513 CAGTAACGACACCATGGCGAGTGGCTGGAGAGCATCTAGTTCCACTTCGATTCGAAGA 572
|||||
Db 1 CAGTAACGACACCATGGCGAGTGGCTGGAGAGCATCTAGTTCCACTTCGATTCGAAGA 60

RESULT 2
ABN47584/c
ID ABN47584 standard; DNA; 60 BP.
XX
XX AC ABN47584;
XX
XX 15-JUL-2002 (first entry)
XX
XX Human spliced transcript detection oligonucleotide SEQ ID NO:20332.
DE
XX Human; mouse; rat; splice transcript; detection; RNA transcript;
KW splice variant; transcriptome; oligonucleotide library; ss.
XX
XX Homo sapiens.
XX
XX WO200210449-A2.
XX
XX 07-FEB-2002.
XX
XX 20-JUL-2001; 2001WO-IB001903.
XX
XX 28-JUL-2000; 2000US-0221607P.
PR
XX 02-MAY-2001; 2001US-0287724P.
XX
XX (COMP-) COMPUGEN INC.
PI Shoshan A, Wasserman A, Mintz E, Mintz L, Faigler S;

```
XX WPI; 2002-257383/30.
DR
XX
PT New oligonucleotide libraries comprising oligonucleotides which
PT selectively hybridize to mRNAs transcribed from a transcription unit of a
PT genome, useful for detecting tissue-, pathology-, and developmental-
PT specific genes.
XX
XX
PS Example 1; SEQ ID NO 20332; 47bp; English.
XX
CC The present invention describes oligonucleotide libraries for detecting
CC messenger RNAs that populate a (sub-)transcriptome, where the (sub-)
CC transcriptome comprises messenger RNAs transcribed from multiple
CC transcription units that populate a genome. The library comprises several
CC oligonucleotides, each capable of hybridizing selectively to a set of
CC messenger RNAs transcribed from a given transcription unit of the genome,
CC which encodes one or more messenger RNA splice variants. The
CC oligonucleotide libraries are useful for detecting mRNAs from a
CC biological sample, in expression profiling studies, in qualitatively or
CC quantitatively characterizing the corresponding transcriptome, and in
CC detecting RNA transcripts and splice variants of human or animal
CC transcriptomes. The libraries may also be used as specialised mini
CC libraries to detect transcripts of a sub-transcriptome under a particular
CC biological or pathological state, and so allowing the detection of tissue
CC - and pathology-specific genes such as those genes only expressed in
CC specific tissue under a specific pathological condition; to detect
CC developmental specific genes; and to detect RNA transcripts and splice
CC variants of a transcriptome of a patient suffering from a particular
CC disorder. ABN27253 to ABN59589 represent oligonucleotide sequences from
CC rats, humans and mice, which are used in the exemplification of the
CC present invention. N.B. The sequence data for this patent did not form
CC part of the printed specification, but was obtained in electronic format
CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 60 BP; 16 A; 14 C; 16 G; 14 T; 0 U; 0 Other;
Query Match 1.3%; Score 9.8; DB 1; Length 60;
Best Local Similarity 58.6%; Pred. No. 0;
Matches 17; Conservative 0; Mismatches 12; Indels 0; Gaps 0;
QY 477 CTCCTTGTCACCTCCTACTCGTTTCAATA 505
Db ||||| ||||| ||||| |||||
32 CTCCTCAGCCACTCGCCATGCTGTCGTGA 4
Search completed: January 31, 2005, 16:21:35
Job time : 0.001 secs
```

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: January 31, 2005, 16:20:13 ; Search time 0.001 Seconds
(without alignments)
162.392 Million cell updates/sec

Title: us-10-063-553-47
Perfect score: 766
Sequence: 1 ggctcgagcgtttctgagcc.....agtagttgaaaaa 766

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 1 seqs, 106 residues

Total number of hits satisfying chosen parameters: 2

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : abs72969.geneseqn2002as.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	70	9.1	106	1 ABS72969	Human gene trapped
2	15.8	2.1	106	1 ABS72969	Human gene trapped

ALIGNMENTS

RESULT 1	
ABS72969	
ID	ABS72969 standard; cDNA; 106 BP.
XX	
AC	ABS72969;
XX	
DT	03-DEC-2002 (first entry)
XX	
DE	Human gene trapped sequence (GTS) #929.
XX	
KW	Human; gene trapped sequence; GTS; gene; ss; cancer; autoimmune disease;
KW	lupus; scleroderma; Crohn's disease; multiple sclerosis; immune disorder;
KW	inflammatory bowel disease; schizophrenia; psychosis; osteoarthritis;
KW	inflammatory disorder; diabetes; skin disorder; acne; eczema; asthma;
KW	rheumatoid arthritis; hypertension; atherosclerosis; Alzheimer's disease;
KW	cardiovascular disease; Parkinson's disease; osteoporosis; infertility;
KW	bacterial infection; parasitic infection; fungal infection;
XX	
OS	Homo sapiens.
XX	
PN	US2002095031-A1.
XX	
PD	18-JUL-2002.
XX	
PF	03-MAY-2000; 2000US-00563817.

XX	04-MAY-1999; 99US-0132343P.
PR	
PA	(NEHL/) NEHLS M C.
PA	(ZAMB/) ZAMEROWICZ B.
PA	(SAND/) SANDS A T.
XX	
PI	Nehls MC, Zambrowicz B, Sands AT;
XX	
WPI	2002-656030/70.
XX	
PT	New isolated or purified human gene trapped sequences, useful for gene discovery, as markers for gene expression analysis, identifying and mapping the coding regions of human genome, or determining the genetic basis of human disease.
PT	
XX	
PS	Claim 1; SEQ ID NO 937; 36pp; English.
XX	
CC	The invention relates to isolated or purified polynucleotides that correspond to human gene trapped sequences (GTSS). The human GTSS are useful for gene discovery and as markers for gene expression analysis, for identifying and mapping the coding regions of the mammalian, particularly human, genome, for forensic analysis, and for determining the genetic basis of human disease. The peptides and proteins encoded by the polynucleotides are useful for generating antibodies, as reagents in diagnostic assays and in identifying other cellular gene products involved in the regulation of development and cellular differentiation of various cell types. The peptides are also useful as reagents in assays for screening of compounds used in treating disorders affecting development and cell differentiation. The GTSS are also useful in treating or ameliorating diseases associated with the expression of mutant or normal variants of the GTSS, e.g. cancer, autoimmune diseases, lupus, scleroderma, Crohn's disease, multiple sclerosis, inflammatory bowel disease, immune disorders, schizophrenia, psychosis, inflammatory disorders, diabetes, skin disorders such as acne or eczema, osteoarthritis, rheumatoid arthritis, hypertension, atherosclerosis, cardiovascular diseases, Alzheimer's disease, Parkinson's disease, osteoporosis, asthma, infertility, and viral, parasitic, fungal or bacterial infections. This sequence represents a human GTS of the invention
XX	
SQ	Sequence 106 BP; 26 A; 21 C; 28 G; 26 T; 0 U; 5 Other;
	Query Match 9.1%; Score 70; DB 1; Length 106;
	Best Local Similarity 88.7%; Pred. No. 0;
	Matches 94; Conservative 0; Mismatches 10; Indels 2; Gaps 2;
QY	236 CTTGACAGCAAGAAAAGAGCGGTGTCACACAGCACTGGAATGTTTTCAT-CA 294
Db	1 CTTGACAGCAGGAAAAGAGCGGCTGCNACAGCACTGGAATGTTTTCATCA 60
QY	295 TTTTCAGTGTGA-TCACAGTCATGCTGCTCTATTGCATGCTG 339
Db	61 CTTTCAGTGTGAGACACAGTCATGCTGCTGCTGCTGCTGCTGCTGCTG 106
	RESULT 2
	ABS72969/c
ID	ABS72969 standard; cDNA; 106 BP.
XX	
AC	ABS72969;
XX	
DT	03-DEC-2002 (first entry)
XX	
DE	Human gene trapped sequence (GTS) #929.
XX	
KW	Human; gene trapped sequence; GTS; gene; ss; cancer; autoimmune disease;
KW	lupus; scleroderma; Crohn's disease; multiple sclerosis; immune disorder;
KW	inflammatory bowel disease; schizophrenia; psychosis; osteoarthritis;
KW	inflammatory disorder; diabetes; skin disorder; acne; eczema; asthma;
KW	rheumatoid arthritis; hypertension; atherosclerosis; Alzheimer's disease;
KW	cardiovascular disease; Parkinson's disease; osteoporosis; infertility;
KW	bacterial infection; parasitic infection; fungal infection;
XX	
OS	Homo sapiens.
XX	
PN	US2002095031-A1.
XX	
PD	18-JUL-2002.
XX	
PF	03-MAY-2000; 2000US-00563817.

KW bacterial infection; forensic analysis; cellular differentiation.
XX
OS Homo sapiens.
XX
FN US2002095031-A1.
XX
PD 18-JUL-2002.
XX
XX
PF 03-MAY-2000; 2000US-00563917.
XX
PR 04-MAY-1999; 99US-0132343P.
XX
XX (NEHL/) NEHLS M C.
PA (ZAMB/) ZAMBROWICZ B.
PA (SAND/) SANDS A T.
XX
XX Nehls MC, Zambrowicz B, Sands AT;
PI WPI; 2002-656030/70.
XX
XX
XX New isolated or purified human gene trapped sequences, useful for gene
PT discovery, as markers for gene expression analysis, identifying and
PT mapping the coding regions of human genome, or determining the genetic
PT basis of human disease.
XX
PS Claim 1; SEQ ID NO 937; 36pp; English.
XX
XX The invention relates to isolated or purified polynucleotides that
CC correspond to human gene trapped sequences (GTSs). The human GTSs are
CC useful for gene discovery and as markers for gene expression analysis,
CC for identifying and mapping the coding regions of the mammalian,
CC particularly human, genome, for forensic analysis, and for determining
CC the genetic basis of human disease. The peptides and proteins encoded by
CC the polynucleotides are useful for generating antibodies, as reagents in
CC diagnostic assays and in identifying other cellular gene products
CC involved in the regulation of development and cellular differentiation of
CC various cell types. The peptides are also useful as reagents in assays
CC for screening of compounds used in treating disorders affecting
CC development and cell differentiation. The GTSs are also useful in
CC treating or ameliorating diseases associated with the expression of
CC mutant or normal variants of the GTSs, e.g. cancer, autoimmune diseases,
CC lupus, scleroderma, Crohn's disease, multiple sclerosis, inflammatory
CC bowel disease, immune disorders, schizophrenia, psychosis, inflammatory
CC disorders, diabetes, skin disorders such as acne or eczema,
CC osteoarthritis, rheumatoid arthritis, hypertension, atherosclerosis,
CC cardiovascular diseases, Alzheimer's disease, Parkinson's disease,
CC osteoporosis, asthma, infertility, and viral, parasitic, fungal or
CC bacterial infections. This sequence represents a human GTS of the
XX invention
SQ Sequence 106 BP; 26 A; 21 C; 28 G; 26 T; 0 U; 5 Other;

Query Match 2.1%; Score 15.8; DB 1; Length 106;
Best Local Similarity 74.1%; Pred. No. 0;
Matches 20; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 69 CAGCGTCTGGTCTACTGCTGTAGG 95
|||||
Db 28 CAGCCCGCTCTTTTCTCTGTCAAG 2

Search completed: January 31, 2005, 16:20:13
Job time : 0.001 secs